Neuren Phase 2 trial Investor Presentation
Neuren has released a statement that the drug was found to be generally safe at the dose tested, having no serious adverse effects.
Neuren has released a statement that the drug was found to be generally safe at the dose tested, having no serious adverse effects.
Neuren has released a statement that the drug was found to be generally safe at the dose tested, having no serious adverse effects.
This EL-PFDD meeting was modeled after the work of the FDA’s Patient Focused Drug Development (PFDD) initiative. PFDD is a systematic way of gathering patient perspectives on their condition and on available treatments. The information gathered at the meeting is presented in this Voice of the Patient report, a high-level summary of the perspectives generously shared by the families and caregivers of individuals living with PMS, who participated in the November 8, 2022, EL-PFDD meeting. The report also includes selected comments that were submitted through an online portal.